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We are studying the role of sexually transmitted vi­
ruses in the development of human tumors. The persis­
tence of herpes simplex virus, cytomegalovirus, and hu­
man papillomavirus nucleic acid sequences has been 
examined using cloned viral DNA sequences as probes. 
The relationship of the viruses to various stages in the 
progression of neoplasia is examined, with particular 
reference to the role of viral and/or cellular genes in the 
initiation, promotion, and maintenance of the neoplastic 
phenotype. The human tumors of major interest in this 
context are carcinomas of the cervix, vulva, and anus 
and Kaposi's sarcoma. 
The minimal fragment of HSV-2 DNA detected in 
cervical tumors is contained within a 656-bp sequence 
that can be used in transfection experiments to trans­
form rodent cells in vitro to a malignant phenotype. 
However, neither this fragment nor any other is con­
sistently retained in cervical tumors, suggesting that 
this viral DNA may initiate but not maintain the trans­
formed phenotype. 
Herpesviruses are widespread in humans, primates, and other 
animals and are the causative agents of diseases ranging from 
relatively mild skin eruptions to severe and frequently fatal 
encephalitis. Some members of the group Herpetoviridae are 
convincingly associated with naturally occurring cancers, e.g., 
Marek's disease virus (MDV) in poultry, Lucke carcinoma in 
the frog, and Epstein-Barr virus (EBV) in Burkitt's lymphoma 
and in nasopharyngeal carcinoma in humans. Herpes simplex 
virus types 1 and 2 (HSV-1 and HSV-2) and cytomegalovirus 
(CMV) have been proposed as having etiologic roles in other 
cancers in humans, e.g., uterine cervical carcinoma and other 
urogenital tumors. Herpesviruses are large DNA-containing 
viruses with a virion diameter of 100 nm, although enveloped 
virions may be up to 200 nm in diameter. The molecular weight 
of nucleic acid ranges from 92 to 150 x 106 daltons. 
The suggestion that HSV -2 is involved in the etiology of 
squamous cell carcinoma of the uterine cervix was initially 
based on serologic and epidemiologic studies. Supporting evi­
dence came from finding viral antigens expressed in tumor 
cells, as well as the detection of viral RNA and DNA in some 
tumors. In addition, HSV-1 and HSV-2 are able to transform 
rodent cells to a malignant phenotype. 
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Infection with cytomegalovirus is very common in humans, 
with approximately 80 percent of the population above the age 
of 35 showing evidence of prior CMV infection as measured by 
complement fixation. The virus can be transmitted by blood 
transfusion, transplacentally, and via milk, urine, and respira­
tory secretions. The majority of CMV infections do not result 
in obvious pathologic changes, although the infection of new­
borns and infants may result in failure to thrive and mental 
retardation. In immunologically deficient individuals, e.g., can­
cer patients and transplant recipients, infection with CMV is 
a serious complication frequently resulting in fatal interstitial 
pneumonia. The findings of CMV viruria in rheumatologic 
patients undergoing immunosuppressive treatment and appar­
ent activation of virus in bone marrow transplant recipients 
are both indirect evidence for CMV latency. 
Human cytomegalovirus is therefore associated with a wide 
range of disease from birth defects and interstitial pneumonia 
to frequent mild subclinical infections, and it has also been 
implicated in a number of human tumors, e.g., prostatic carci­
noma, colon carcinoma, and Kaposi's sarcoma. CMV has been 
reported to transform cells in vitro, either as UV -inactivated 
virus or as cloned fragments of viral DNA. As with HSV-2, a 
defined fragment of viral DNA has been used to induce trans­
formation of rodent cells, but to date, no CMV DNA has been 
clearly detected in these cells. 
HERPES SIMPLEX VIRUS IN CERVICAL 
CARCINOMA 
The increasing prevalence of herpes genitalis as a sexually 
transmitted disease [1] and an increasing incidence of prema­
lignant changes in the exposed tissues of younger women [2] 
have stimulated attempts to establish an association between 
previous infection with herpes simplex virus (HSV) and the 
development of uterine cervical carcinoma. Many epidemiologic 
and serologic studies [3] have indicated a strong correlation 
between neoplastic changes in the cervix and earlier infection 
with HSV-2, and it has furthermore been shown that virus­
specific proteins [4] and ribonucleic acid (RNA) [5] can be 
detected in the neoplastic tissues. Frenkel et al [6] described 
solution hybridization studies on one cervical tumor in which 
a portion of the HSV-2 genome was detected, but subsequent 
similar experiments on a large number of cervical tumors 
provided only negative results [7]. Those experiments, while 
capable of detecting one viral genome per diploid cell, would 
not have resolved small fragments of viral DNA, although a 
transforming gene could be wholly represented within less than 
2 kb of viral DNA [8]. 
Our initial observation that in situ hybridization could be 
used to detect HSV RNA in human tumor tissues has been 
recently confirmed by other laboratories. We have extended 
these studies by using the cloned subgenomic fragments of 
HSV-2 DNA developed in this laboratory [10] as probes for in 
situ hybridization in order to define regions of the HSV-2 
genome transcribed in cervical biopsies. 
Human cervical tissue was obtained during coloposcopic ex· 
amination from patients who had been referred for evaluation 
of abnormal Papanicolaou smears. Biopsies were taken from 
those areas most likely to contain cervical cancer precursors as 
identified by the colposcope. The biopsies were frozen in a 
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cryostat, the diagnosis confirmed, and permanent diagnostic 
sections were prepared. The tissue remaining following the 
diagnostic evaluation was stored at -70oe until further sections 
were prepared. Benign cervical tissue from normal-appearing 
cervical transformation zones was also obtained from hyster­
ectomy specimens in patients whose uteri were removed for 
other reasons. These were snap-frozen and stored at -70oe. 
The cervical tissues were divided into three categories: (1) 
benign (including squamous metaplasia), (2) cervical intraepi­
thelial neoplasia (eIN), dysplasia, and carcinoma in situ, and 
(3) invasive cancer. 
In a recent series of eIN and invasive carcinoma biopsies, 
cloned and restriction endonuclease-derived fragments of HSV-
2 DNA were hybridized to 75 frozen-sectioned biopsy specimens 
of neoplastic cervical tissue and carcinoma. Another 50 samples 
of nonneoplastic cervical squamous epithelium and frozen sec­
tions from other tissues were hybridized with the HSV -2 probes 
as controls. Heterologous virus probes (simian virus 40, aden­
ovirus 2, and bacteriophage A) were hybridized to replicate 
sections to control for nonspecific binding of nick-translated 
DNA. Because these heterologous probes were never bound to 
specimens negative for HSV, our interpretation is that in those 
specimens binding multiple heterologous probes, the result 
indicates a nonspecific interaction. This occurred in approxi­
mately 10% of the tissues examined. The distribution of posi­
tive hybridization results with HSV-2 DNA probes shows that 
the RNA species detected are limited to three regions of the 
virus genome: positions 0.07 to 0.4, 0.58 to 0.63, and 0.82 to 
0.85. This last region is in the short-repeat sequences and is 
therefore also represented at position 0.94 to 0.96. 
The two regions of HSV -2 DNA described as containing 
transforming genes [11] map between positions 0.4 and 0.63 on 
the genome. Sequences mapping between 0.30 and 0.45 on the 
HSV -1 genome have been shown to have transforming ability 
[12], and DNA mapping within this region has been shown to 
persist in cells transformed by UV-inactivated HSV-2 [13]. 
These transformants are positive by immunofluorescence for 
the viral antigen VP143 [14]. The BglII N region of HSV-2 
that also persists in these cells [15] has been shown to code for 
a 38 K protein [16,17], as well as select RNAs that direct the 
synthesis of four other polypeptides [18]. Sera from patients 
with cervical carcinoma have been reported to precipitate two 
HSV-2 polypeptides (molecular weights 38,000 and 118,000) 
more frequently than did controls (19). Although the 38 K 
protein has been reported in HSV -2 transformed cells [20], we 
have been unable to detect it in any transformed cell line using 
two specific monoclonal antibodies [21). 
We screened replicate samples of the cervical biopsies tested 
by in situ hybridization for HSV RNA for evidence of virus­
specific antigen reactive with antisera to the 38 K and IeSp 
11/12 proteins using an immunoperoxidase staining procedure. 
The monospecific antiserum IeSp 11/12 was positive on virus­
infected and transformed cells and on the neoplastic cells in 
some of the eIN and cervical carcinoma sections. The results 
found with the IeSp 11/12 antisera closely parallel the in situ 
hybridization result. When benign cervical tissue was exam­
ined, HSV antigens were occasionally seen in isolated mature 
squamous epithelial cells near the surface in the portio or 
transformation zone in a pattern suggesting an acute infection. 
In immature squamous metaplastic cells of the transformation 
zone or in basal cell hyperplasia, the cells that were positive 
were in a basal location rather than a superficial one. Approx­
imately 30% of the sections classified as eIN I, II, or III had 
detectable antigen, which was limited to the neoplastic cells, 
similar to the result found in vulvar intraepithelial neoplasia, 
and approximately 20% of the invasive squamous cell tumors 
were positive. In each case, preabsorption of the serum with 
HSV-2 infected cell lysates inhibited the staining reaction. The 
pattern and number of positive antiserum-antigen reactions in 
infected cells, in vitro transformed cells, and neoplastic cells 
indicated that the two antisera IeSp 11/12 and VP143 might 
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be detecting the same protein. We therefore used these antisera 
in immunoprecipitation studies with extracts of HSV -2 infected 
cells. The two antisera precipitated a single band with identical 
electrophoretic mobility and an estimated molecular weight of 
118,000, thus providing evidence for a single identity for IeSp 
11/12 and VP143. The detection of IeSp 11/12 in neoplastic 
cells is not, by itself, sufficient to implicate HSV -2 because it 
has been shown that at least five different herpesviruses induce 
proteins that cross-react with IeSp 11/12 (22). 
The monoclonal antiserum to the 38 K protein was negative 
on all specimens of cervical carcinoma tested, although it was 
extremely sensitive when used in serotyping HSV in culture 
and in patient specimens (21). 
We have recently examined a number of surgically removed 
uterine tumors together with serum samples from these pa­
tients. In preliminary experiments, DNA from a series of tu­
mors was digested with restriction endonuclease EcoRI, elec­
trophoresced through agarose gels, transferred to nitrocellulose 
filters, and hybridized to :l2P-labeled plasmid DNA containing 
cloned HSV-2 DNA sequences or to fragments of viral DNA 
released from the plasmid. Hybridization was achieved with 
three of the tumor DNA samples examined, and for further 
analysis, these were cleaved with PstI and hybridized with the 
four PstI fragments of the HSV-2 BglII N fragment and with 
deletion mutants prepared from one of these fragments (Gal­
loway et aI, in preparation; see Fig 1). This localized the virus­
specific DNA to a 656-bp sequence within BglII N. 
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FIG 1. Detection of sequences homologous to HSV -2 DNA fragment 
BC24 in cervical carcinoma tumor DNA. Ten micrograms of DNA 
from tumors W, T, and H were digested with endonuclease PstI, 
fractionated by electrophoresis through 0.7% agarose, hybridized to 
a2P-labeled viral DNA, and exposed for autoradiography. Lane 4 con­
tains a reconstruction of HSV -2 BglII N P2 DNA representing five 
copies of plasmid DNA per diploid genome of human placental DNA. 
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Serum samples obtained from the patients at the time of 
surgery were examined for antibodies to HSV by complement 
fixation (CF) and immunoprecipitation (IP) assays. The results 
from four samples are shown in Fig 2. The serum from patient 
W had no detectable CF titer (1:8) and did not give significant 
immunoprecipitation with HSV-1 or HSV-2. Serum D, from a 
patient positive for BglII N sequences by Southern blot hybrid­
ization, had a CF titer of 1:128 for HSV and gave significantly 
higher reactivity in the IP test when compared with other 
patients' sera. However, antibody to the 38 K protein encoded 
within the BglII N sequences, which is precipitated by the 
monoclonal antibody designated H -11, was not a significant 
component of serum D. 
Cloning of the viral DNA sequences, together with presumed 
flanking cellular sequences, will provide more information on 
the state of the viral DNA. The problems encountered in 
attempts to define a single gene in HSV that is responsible for 
transformation and which encodes a product universally found 
in transformed and tumor cells, as is the case for other DNA 
tumor viruses, has engendered speculation about synergistic or 
mutational events involving HSV infection in the genesis of 
uterine cancer [23,24). 
All this leaves us unable to reach any firm conclusion about 
a possible role for HSV in human tumors. Does the virus act 
as a mutagen'? Recent results from zur Hausen's laboratory 
have demonstrated mutagenic activity (25). Definition of the 
genes involved in mutagenesis will also determine whether they 
are the same as those involved in transformation. 
Is transformation-or mutagenesis-the result of a "hit-and­
run "mechanism [26]? The failure to detect a consistent set of 
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FIG 2. Immunoprecipitation of HSV·2 polypeptides with antisera 
from patients with cervical tumors. Cell extracts containing either 
HSV -1 or HSV·2 polypeptides labeled with e5S ]methionine were pre· 
pared as described previously [18] . In the reactions marked S, W, M, 
P, and D human antisera were used: S was from a normal individual 
with no known current or recurrent herpetic infection; the other sera 
were from patients with cervical tumors. Each of these sera was reacted 
with HSV·l proteins (left) and HSV·2 proteins (right). Antibody H-
11 is a monoclonal antibody that precipitates two proteins of 140,000 
and 38,000 daltons from HSV·2 infected cells. In immunoblots, how­
ever, there is a preferential reaction for the 38 kilodalton protein. 
Antibody E·12 is a monoclonal antibody that precipitates a complex of 
proteins of 50,000 to 55,000 daltons from HSV -2 infected cells. Anti· 
body G·ll is a monoclonal antibody that reacts with the HSV-1 gC 
glycoprotein. ICSP 11·12 is a polyclonal antiserum to the major HSV· 
2 DNA·binding protein (a gift of Drs. K. Powell and D. Purifoy, Leeds). 
The last lane contains molecular-weight markers. The immunopre­
cipitation reactions, as described previously (Galloway et ai, 1982), 
were analyzed by SDS-polyacrylamide gel electrophoresis in 11 % slab 
gels with N,N1-dially-tartardiamide (DATD) as a linker . Autoradiog­
raphy was enhanced by tluorograpby using Enhance (New England 
Nuclear Corp.), and the gel was exposed for 7 days. 
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viral nucleic acid sequences or proteins in tumors or trans­
formed cells at least leaves the question open. Either muta­
genesis or a "hit-and-run" mechanism could result in the acti­
vation of cellular oncogenes, but we do not so far have any firm 
evidence in support of either hypothesis. 
CYTOMEGALOVIRUS AND KAPOSI'S SARCOMA 
Cytomegalovirus has been linked to Kaposi's sarcoma by 
various methods, including the detection of CMV antibodies 
[27] , CMV-related antigens [28], and CMV DNA [29]. We have 
recently received a number of biopsies, tumor samples, and cell 
lines from patients with Kaposi's sarcoma. Although most of 
the studies are in a very preliminary stage, we have reported 
on one case [30], that of a young homosexual man who devel­
oped Kaposi's sarcoma following chemotherapy for testicular 
cancer. Using the in situ cytologic hybridization technique for 
the detection of CMV genetic material, we were able to localize 
CMV -specific mRNA in Kaposi's sarcoma cells. 
Immunoperoxidase staining for factor VIII was performed 
using an antibody to factor VIII (Immulock). The neoplastic 
cells were focally positive, demonstrating the endothelial nature 
of the neoplasm, a feature of Kaposi's sarcoma [81]. 
The stained autoradiographs from the in situ hybridization 
for both CMV and HSV on the skin lesion were examined. 
Herpes simplex virus was not demonstrated in any areas of the 
biopsy material. In contrast, the skin lesion, exposed to radio­
active cytomegalovirus DNA as a probe, revealed that autora­
diographic grains were localized to the proliferating Kaposi 
cells in the deep dermis. There was a precise localization of 
these auto radiographic grains immediately over the proliferat­
ing Kaposi cells. No evidence of cytomegaly or nuclear inclu­
sions was seen in any of the cells with overlying autoradi­
ographic grains. No virus was isolated from the tissue sample. 
The patient's serum was positive for CMV by complement 
fixation at a dilution of 1:8. 
To date we have extracted cellular DNA from 26 different 
specimens including tumor cell lines and lung and spleen tu­
mors from an individual with disseminated Kaposi's sarcoma. 
The CMV pCM1058 probe [32,33] hybridized extensively to all 
the cell lines tested as well as the lung and spleen tumor tissue. 
The EcoRI R fragment also hybridized to all the cell lines and 
tumor samples tested. A 558-bp deletion fragment, pCM4127, 
located at the right-hand end of EcoRI R also hybridized to 
several of the cell lines and to both tumor samples. The probe 
pCM1058 and the subclones EcoRI R and pCM4127 were later 
found to hybridize weakly to human DNA. To avoid this 
problem, we utilized the EcoRI J fragment , which does not 
hybridize to human DNA and contains sequences coding for 
the major IE 72 K protein. The results of the hybridization of 
this fragment indicated that only the tumor tissues contain 
sequences from this region. The dot-blot hybridization with the 
EcoRI ,J fragment (Fig 3) showed that the sequences were 
present in many copies, and Southern blot analysis of the 
tumor tissue demonstrated multiple copies of the CMV se­
quence (Fig 4). These preliminary results indicate that CMV is 
present in Kaposi's tumor tissue. However, further tests are 
necessary to establish the presence or absence of other CMV 
DNA fragments in the cell lines derived from tumor tissue. 
PAPILLOMAVIRUSES AND CERVICAL CARCINOMA 
The recent reports of the presence of human papillomavirus 
(HPV) DNA sequences in cervical tumors [34,35] have encour­
aged us to utilize the biotin-avidin procedure (36) for in situ 
hybridization with cloned HPV probes in order to compare 
results obtained from that method with results from Southern 
[37] blot procedures. Previous work by Orth and his collabo­
rators [38] has shown detection of papillomavirus DNA in 
warts and carcinomas using in situ hybridization and radioac­
tive probes. We have used the biotin-label procedure because it 
duly 1984 
provides rapid results, can be used on routinely fixed, sectioned, 
and stored tissue, and may therefore also be used for retrospec­
tive diagnosis. 
We have demonstrated that both HSV and HPV sequences 
Hybridization of AIDS Cell Lines and Kaposi� 
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can be detected in the same tumor. The in situ hybridizations 
have shown that the HPV sequences, in samples described as 
squamous or adenosquamous carcinomas, may in fact be con­
tained in cells that are in small areas of apparently condyloma-
Southern blot of AIDS cell lines and Kaposi's sarcoma 
tumers hybridized with the EceRI J frogment 
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FIG 4. Southern hlot of AIDS cell lines and Kaposi's sarcoma tu­
mors hybridized witb cloned n'coRI.J fragment ofCMV (AD169) DNA. 
FIG 5. In situ hybridization of HPV 
6 DNA probe labeled with biotin to ad­
enosquamous carcinoma of the cervix, A, 
Arrow indicates positive area. B, Higher 
power of positive cells. 
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like tissue rather than in the squamous carcinoma tissue (Fig 
5). It is therefore prudent to carefully check both the routine 
histology and the in situ hybridization results before reaching 
conclusions about the role of HPV in cervical carcinoma, al­
though the results of Durst et al [35] show that the presence of 
HPV in these tumors is probably very significant in the devel­
opment of the tumor. 
The authors would like to thank Dr. K. Shriver for the gel in Fig 2. 
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